Product Description
Dimethyl Sulfoxide is a highly polar organic liquid that is used widely as a chemical solvent and a free radical scavenger. It shows a range of pharmacological activity including analgesia and anti-inflammation. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect cells and tissue during cryopreservation and has been used to treat extravasation damage caused by anthracycline-based chemotherapy. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Dimethyl-sulfoxide)
Mechanisms of Action: Free Radical Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Egypt | Estonia | Germany | Greece | Hong Kong | Hungary | Japan | Jordan | Korea | Russia | Singapore | Spain | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: HERMAL Kurt Herrmann &OHG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Denmark, Italy
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Graft vs Host Disease|Heart Failure, Chronic|Heart Failure, Systolic|Keratoconjunctivitis Sicca
Phase 1: Melanoma|Skin Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12624000310561 |
ACTRN12624000310561 | P1 |
Recruiting |
Skin Cancer|Melanoma |
2025-08-30 |
2026-01-12 |
Treatments |
|
2025-520837-22-00 |
2025-520837-22-00 | P2 |
Not yet recruiting |
Heart Failure, Chronic|Heart Failure, Systolic |
2028-09-01 |
12% |
||
2023-507561-26-00 |
NGF0123 | P2 |
Completed |
Keratoconjunctivitis Sicca |
2024-11-22 |
2025-05-02 |
Treatments |
|
CTR20232192 |
CTR20232192 | P2 |
Recruiting |
Graft vs Host Disease |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |